VIVOSIM LABS INC (VIVS) Stock Fundamental Analysis

NASDAQ:VIVS • US68620A3023

2.17 USD
-0.06 (-2.69%)
At close: Feb 27, 2026
2.11 USD
-0.06 (-2.76%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

VIVS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. While VIVS seems to be doing ok healthwise, there are quite some concerns on its profitability. VIVS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • VIVS had positive earnings in the past year.
  • In the past year VIVS has reported a negative cash flow from operations.
  • VIVS had negative earnings in each of the past 5 years.
  • VIVS had a negative operating cash flow in each of the past 5 years.
VIVS Yearly Net Income VS EBIT VS OCF VS FCFVIVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • VIVS has a better Return On Assets (-20.47%) than 75.86% of its industry peers.
  • VIVS's Return On Equity of -28.07% is fine compared to the rest of the industry. VIVS outperforms 77.59% of its industry peers.
Industry RankSector Rank
ROA -20.47%
ROE -28.07%
ROIC N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
VIVS Yearly ROA, ROE, ROICVIVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • With an excellent Gross Margin value of 98.57%, VIVS belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
  • VIVS's Gross Margin has improved in the last couple of years.
  • VIVS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
VIVS Yearly Profit, Operating, Gross MarginsVIVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VIVS has less shares outstanding
  • The number of shares outstanding for VIVS has been reduced compared to 5 years ago.
  • There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIVS Yearly Shares OutstandingVIVS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VIVS Yearly Total Debt VS Total AssetsVIVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • VIVS has an Altman-Z score of -52.43. This is a bad value and indicates that VIVS is not financially healthy and even has some risk of bankruptcy.
  • VIVS's Altman-Z score of -52.43 is on the low side compared to the rest of the industry. VIVS is outperformed by 90.80% of its industry peers.
  • VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -52.43
ROIC/WACCN/A
WACC8.61%
VIVS Yearly LT Debt VS Equity VS FCFVIVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • VIVS has a Current Ratio of 3.10. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
  • VIVS has a worse Current ratio (3.10) than 63.60% of its industry peers.
  • A Quick Ratio of 3.10 indicates that VIVS has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.10, VIVS is not doing good in the industry: 61.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.1
Quick Ratio 3.1
VIVS Yearly Current Assets VS Current LiabilitesVIVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 278.71% over the past year.
  • VIVS shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.92%.
  • The Revenue for VIVS have been decreasing by -42.03% on average. This is quite bad
EPS 1Y (TTM)278.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-589.48%
Revenue 1Y (TTM)35.92%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-6.67%

3.2 Future

  • VIVS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.30% yearly.
  • VIVS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.82% yearly.
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIVS Yearly Revenue VS EstimatesVIVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M
VIVS Yearly EPS VS EstimatesVIVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2024 2025 2026 2027 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 1.14, which indicates a rather cheap valuation of VIVS.
  • 99.81% of the companies in the same industry are more expensive than VIVS, based on the Price/Earnings ratio.
  • VIVS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.07.
  • VIVS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 1.14
Fwd PE N/A
VIVS Price Earnings VS Forward Price EarningsVIVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVS Per share dataVIVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • VIVS's earnings are expected to decrease with -6.30% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.44
PEG (5Y)N/A
EPS Next 2Y-6.3%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VIVS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIVOSIM LABS INC

NASDAQ:VIVS (2/27/2026, 8:00:02 PM)

After market: 2.11 -0.06 (-2.76%)

2.17

-0.06 (-2.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)06-03
Inst Owners8.59%
Inst Owner ChangeN/A
Ins Owners0.6%
Ins Owner Change77.05%
Market Cap5.66M
Revenue(TTM)140.00K
Net Income(TTM)-1.98M
Analysts45.71
Price TargetN/A
Short Float %30.87%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33.96%
Min Revenue beat(2)-45.1%
Max Revenue beat(2)-22.82%
Revenue beat(4)1
Avg Revenue beat(4)-26.44%
Min Revenue beat(4)-46.52%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-32.76%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 1.14
Fwd PE N/A
P/S 40.46
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)1.91
EY88.02%
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-3.89
FCFYN/A
OCF(TTM)-3.89
OCFYN/A
SpS0.05
BVpS2.71
TBVpS2.71
PEG (NY)0.44
PEG (5Y)N/A
Graham Number10.79
Profitability
Industry RankSector Rank
ROA -20.47%
ROE -28.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.57%
FCFM N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.1
Quick Ratio 3.1
Altman-Z -52.43
F-Score4
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)52.61%
Cap/Depr(5y)295.14%
Cap/Sales(3y)51.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)278.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-589.48%
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)35.92%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-6.67%
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.48%
OCF growth 3YN/A
OCF growth 5YN/A

VIVOSIM LABS INC / VIVS FAQ

What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to VIVS.


Can you provide the valuation status for VIVOSIM LABS INC?

ChartMill assigns a valuation rating of 4 / 10 to VIVOSIM LABS INC (VIVS). This can be considered as Fairly Valued.


What is the profitability of VIVS stock?

VIVOSIM LABS INC (VIVS) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for VIVS stock?

The Price/Earnings (PE) ratio for VIVOSIM LABS INC (VIVS) is 1.14 and the Price/Book (PB) ratio is 0.8.


What is the expected EPS growth for VIVOSIM LABS INC (VIVS) stock?

The Earnings per Share (EPS) of VIVOSIM LABS INC (VIVS) is expected to grow by 2.6% in the next year.